;PMID: 11698147
;source_file_2872.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..229] = [t:48..229]
;2)section:[e:233..245] = [t:233..245]
;3)section:[e:249..426] = [t:249..426]
;4)sentence:[e:430..638] = [t:430..638]
;5)sentence:[e:639..722] = [t:639..722]
;6)sentence:[e:723..963] = [t:723..963]
;7)sentence:[e:964..1115] = [t:964..1115]
;8)sentence:[e:1116..1342] = [t:1116..1342]
;9)section:[e:1346..1391] = [t:1346..1391]

;section 0 Span:0..42
;Neurosci Lett.  2001 Nov 13;314(1-2):61-4.
(SEC
  (FRAG (NNP:[0..8] Neurosci) (NNP:[9..13] Lett) (.:[13..14] .)
        (CD:[16..20] 2001) (IN:[21..24] Nov) (CD:[25..32] 13;314-LRB-)
        (NN:[32..35] 1-2) (-RRB-:[35..36] -RRB-) (::[36..37] :) (CD:[37..39] 61)
        (CD:[39..42] -4.)))

;sentence 1 Span:48..229
;Hypoxanthine-guanine phosphoribosyltransferase-deficiency produces aberrant 
;neurite outgrowth of rodent neuroblastoma used to model the neurological 
;disorder Lesch Nyhan syndrome.
;[48..94]:gene-protein:"Hypoxanthine-guanine phosphoribosyltransferase"
;[153..166]:malignancy-type:"neuroblastoma"
;[208..228]:malignancy-type:"Lesch Nyhan syndrome"
(SENT
  (S-HLN
    (NP-SBJ
      (NML
        (NML (NN:[48..60] Hypoxanthine) (HYPH:[60..61] -) (NN:[61..68] guanine))
        (NN:[69..94] phosphoribosyltransferase))
      (HYPH:[94..95] -) (NN:[95..105] deficiency))
    (VP (VBZ:[106..114] produces)
      (NP
        (NP
          (NP (JJ:[115..123] aberrant) (NN:[125..132] neurite)
              (NN:[133..142] outgrowth))
          (PP (IN:[143..145] of)
            (NP (NN:[146..152] rodent) (NN:[153..166] neuroblastoma))))
        (VP (VBN:[167..171] used) (-NONE-:[171..171] *)
          (S-PRP
            (NP-SBJ (-NONE-:[171..171] *))
            (VP (TO:[172..174] to)
              (VP (VB:[175..180] model)
                (NP
                  (NP (DT:[181..184] the) (JJ:[185..197] neurological)
                      (NN:[199..207] disorder))
                  (NP (NNP:[208..213] Lesch) (NNP:[214..219] Nyhan)
                      (NN:[220..228] syndrome)))))))))
    (.:[228..229] .)))

;section 2 Span:233..245
;Connolly GP.
(SEC
  (FRAG (RB:[233..241] Connolly) (NN:[242..244] GP) (.:[244..245] .)))

;section 3 Span:249..426
;Purine NeuroScience Laboratory, Chemical Pathology, Guy's King's and St.
;Thomas'  Medical School, Kings College London, Guy's Hospital, London SE1
;9RT, UK.  g.connolly@ucl.ac.uk
(SEC
  (FRAG (NN:[249..255] Purine) (NNP:[256..268] NeuroScience)
        (NNP:[269..279] Laboratory) (,:[279..280] ,) (NNP:[281..289] Chemical)
        (NNP:[290..299] Pathology) (,:[299..300] ,) (NNP:[301..304] Guy)
        (POS:[304..306] 's) (NNP:[307..311] King) (POS:[311..313] 's)
        ($:[314..317] and) (NNP:[318..321] St.) (NNP:[322..328] Thomas)
        (POS:[328..329] ') (NNP:[331..338] Medical) (NNP:[339..345] School)
        (,:[345..346] ,) (NNP:[347..352] Kings) (NNP:[353..360] College)
        (NNP:[361..367] London) (,:[367..368] ,) (NNP:[369..372] Guy)
        (POS:[372..374] 's) (NNP:[375..383] Hospital) (,:[383..384] ,)
        (NNP:[385..391] London) (NNP:[392..395] SE1) (NNP:[396..399] 9RT)
        (,:[399..400] ,) (NNP:[401..404] UK.) (NNP:[406..420] g.connolly@ucl)
        (.:[420..426] .ac.uk)))

;sentence 4 Span:430..638
;Lesch Nyhan syndrome (LNS) manifests in bizarre and horrific neurological 
;symptoms, the primary cause being a deficiency of the purine salvage enzyme, 
;hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
;[430..450]:malignancy-type:"Lesch Nyhan syndrome"
;[452..455]:malignancy-type:"LNS"
;[583..629]:gene-protein:"hypoxanthine-guanine phosphoribosyltransferase"
;[631..636]:gene-protein:"HGPRT"
(SENT
  (S
    (NP-SBJ
      (NP (NNP:[430..435] Lesch) (NNP:[436..441] Nyhan) (NN:[442..450] syndrome))
      (NP (-LRB-:[451..452] -LRB-) (NN:[452..455] LNS) (-RRB-:[455..456] -RRB-)))
    (VP (VBZ:[457..466] manifests)
      (PP (IN:[467..469] in)
        (NP
          (ADJP (JJ:[470..477] bizarre) (CC:[478..481] and)
                (JJ:[482..490] horrific))
          (JJ:[491..503] neurological) (NNS:[505..513] symptoms)))
      (,:[513..514] ,)
      (S-ADV
        (NP-SBJ (DT:[515..518] the) (JJ:[519..526] primary)
                (NN:[527..532] cause))
        (VP (VBG:[533..538] being)
          (NP-PRD
            (NP (DT:[539..540] a) (NN:[541..551] deficiency))
            (PP (IN:[552..554] of)
              (NP
                (NP (DT:[555..558] the)
                  (NML (JJ:[559..565] purine) (NN:[566..573] salvage))
                  (NN:[574..580] enzyme))
                (,:[580..581] ,)
                (NP
                  (NP
                    (NML (NN:[583..595] hypoxanthine) (HYPH:[595..596] -)
                         (NN:[596..603] guanine))
                    (NN:[604..629] phosphoribosyltransferase))
                  (NP (-LRB-:[630..631] -LRB-) (NN:[631..636] HGPRT)
                      (-RRB-:[636..637] -RRB-)))))))))
    (.:[637..638] .)))

;sentence 5 Span:639..722
;How and why this enzyme  deficiency leads to abnormal brain development is
;unknown.
(SENT
  (S
    (SBAR-NOM-SBJ
      (WHADVP-1 (WRB:[639..642] How) (CC:[643..646] and) (WRB:[647..650] why))
      (S
        (NP-SBJ (DT:[651..655] this) (NN:[656..662] enzyme)
                (NN:[664..674] deficiency))
        (VP (VBZ:[675..680] leads)
          (PP (TO:[681..683] to)
            (NP (JJ:[684..692] abnormal) (NN:[693..698] brain)
                (NN:[699..710] development)))
          (ADVP-1 (-NONE-:[710..710] *T*)))))
    (VP (VBZ:[711..713] is)
      (ADJP-PRD (JJ:[714..721] unknown)))
    (.:[721..722] .)))

;sentence 6 Span:723..963
;To investigate this  phenomenon the present study was designed to examine if
;the growth of two  HGPRT-deficient neuroblastomas, mouse N2aTG and rat
;B103-4C was different with  respect to their corresponding control cell
;lines, N2a and B103.
;[819..824]:gene-protein:"HGPRT"
;[835..849]:malignancy-type:"neuroblastomas"
(SENT
  (S
    (S-PRP
      (S
        (NP-SBJ (-NONE-:[723..723] *))
        (VP (TO:[723..725] To)
          (VP (VB:[726..737] investigate)
            (NP (DT:[738..742] this) (NN:[744..754] phenomenon))))))
    (NP-SBJ-1 (DT:[755..758] the) (JJ:[759..766] present) (NN:[767..772] study))
    (VP (VBD:[773..776] was)
      (VP (VBN:[777..785] designed)
        (S
          (NP-SBJ-1 (-NONE-:[785..785] *))
          (VP (TO:[786..788] to)
            (VP (VB:[789..796] examine)
              (SBAR (IN:[797..799] if)
                (S
                  (NP-SBJ
                    (NP (DT:[800..803] the) (NN:[804..810] growth))
                    (PP (IN:[811..813] of)
                      (NP
                        (NP (CD:[814..817] two)
                          (ADJP (NN:[819..824] HGPRT) (HYPH:[824..825] -)
                                (JJ:[825..834] deficient))
                          (NNS:[835..849] neuroblastomas))
                        (,:[849..850] ,)
                        (NP
                          (NP (NN:[851..856] mouse) (NN:[857..862] N2aTG))
                          (CC:[863..866] and)
                          (NP (NN:[867..870] rat) (NN:[871..878] B103-4C))))))
                  (VP (VBD:[879..882] was)
                    (ADJP-PRD (JJ:[883..892] different)
                      (PP (IN:[893..897] with)
                        (NP
                          (NP (NN:[899..906] respect))
                          (PP (TO:[907..909] to)
                            (NP
                              (NP (PRP$:[910..915] their)
                                  (VBG:[916..929] corresponding)
                                  (NN:[930..937] control) (NN:[938..942] cell)
                                  (NNS:[943..948] lines))
                              (,:[948..949] ,)
                              (NP (NN:[950..953] N2a) (CC:[954..957] and)
                                  (NN:[958..962] B103)))))))))))))))
    (.:[962..963] .)))

;sentence 7 Span:964..1115
;Data is  provided showing that compared to control cell lines,
;HGPRT-deficient cells  proliferated less and exhibited greater morphological
;complexity.
;[1027..1032]:gene-protein:"HGPRT"
(SENT
  (S
    (NP-SBJ-2 (NN:[964..968] Data)
      (S-1 (-NONE-:[968..968] *ICH*)))
    (VP (VBZ:[969..971] is)
      (VP (VBN:[973..981] provided)
        (NP-2 (-NONE-:[981..981] *))
        (S-1
          (NP-SBJ (-NONE-:[981..981] *))
          (VP (VBG:[982..989] showing)
            (SBAR (IN:[990..994] that)
              (S
                (PP (VBN:[995..1003] compared)
                  (PP (TO:[1004..1006] to)
                    (NP (NN:[1007..1014] control) (NN:[1015..1019] cell)
                        (NNS:[1020..1025] lines))))
                (,:[1025..1026] ,)
                (NP-SBJ
                  (NML (NN:[1027..1032] HGPRT) (HYPH:[1032..1033] -)
                       (JJ:[1033..1042] deficient))
                  (NNS:[1043..1048] cells))
                (VP
                  (VP (VBD:[1050..1062] proliferated)
                    (ADVP (RBR:[1063..1067] less)))
                  (CC:[1068..1071] and)
                  (VP (VBD:[1072..1081] exhibited)
                    (NP (JJR:[1082..1089] greater)
                        (JJ:[1090..1103] morphological)
                        (NN:[1104..1114] complexity))))))))))
    (.:[1114..1115] .)))

;sentence 8 Span:1116..1342
;If these  abnormalities occur during neurogenesis of human HGPRT-deficient
;brain neurones,  they could profoundly influence central nervous system
;development and thus, may  form the aetiological basis for the symptoms of
;LNS.
;[1175..1180]:gene-protein:"HGPRT"
;[1338..1341]:malignancy-type:"LNS"
(SENT
  (S
    (SBAR (IN:[1116..1118] If)
      (S
        (NP-SBJ (DT:[1119..1124] these) (NNS:[1126..1139] abnormalities))
        (VP (VBP:[1140..1145] occur)
          (PP-TMP (IN:[1146..1152] during)
            (NP
              (NP (NN:[1153..1165] neurogenesis))
              (PP (IN:[1166..1168] of)
                (NP (JJ:[1169..1174] human)
                  (ADJP (NN:[1175..1180] HGPRT) (HYPH:[1180..1181] -)
                        (JJ:[1181..1190] deficient))
                  (NN:[1191..1196] brain) (NNS:[1197..1205] neurones))))))))
    (,:[1205..1206] ,)
    (NP-SBJ (PRP:[1208..1212] they))
    (VP
      (VP (MD:[1213..1218] could)
        (VP
          (ADVP (RB:[1219..1229] profoundly))
          (VB:[1230..1239] influence)
          (NP
            (NML (JJ:[1240..1247] central) (JJ:[1248..1255] nervous)
                 (NN:[1256..1262] system))
            (NN:[1263..1274] development))))
      (CC:[1275..1278] and)
      (VP
        (ADVP (RB:[1279..1283] thus))
        (,:[1283..1284] ,) (MD:[1285..1288] may)
        (VP (VB:[1290..1294] form)
          (NP
            (NP (DT:[1295..1298] the) (JJ:[1299..1311] aetiological)
                (NN:[1312..1317] basis))
            (PP (IN:[1318..1321] for)
              (NP
                (NP (DT:[1322..1325] the) (NNS:[1326..1334] symptoms))
                (PP (IN:[1335..1337] of)
                  (NP (NN:[1338..1341] LNS)))))))))
    (.:[1341..1342] .)))

;section 9 Span:1346..1391
;PMID: 11698147 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1346..1350] PMID) (::[1350..1351] :) (CD:[1352..1360] 11698147)
        (NN:[1361..1362] -LSB-) (NNP:[1362..1368] PubMed) (::[1369..1370] -)
        (NN:[1371..1378] indexed) (IN:[1379..1382] for)
        (NNP:[1383..1391] MEDLINE-RSB-)))
